Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting
Rhea-AI Summary
Ocular Therapeutix (NASDAQ: OCUL) has announced multiple presentations scheduled for the Angiogenesis, Exudation, and Degeneration 2025 virtual meeting on February 8, 2025. The presentations will focus on their key product OTX-TKI, featuring three distinct sessions:
1. Dr. Carl J. Danzig will present on OTX-TKI's progression from Phase 1 to Phase 3, discussing the SOL-1 and SOL-R trials for neovascular AMD at 2:30 PM ET.
2. Dr. Mark R. Barakat will share Phase 1 results of the intravitreal axitinib implant (OTX-TKI) for treating non-proliferative diabetic retinopathy at 5:20 PM ET.
3. Dr. Justis P. Ehlers will present volumetric macular fluid analysis findings from the HELIOS Clinical Trial at 5:25 PM ET, examining the impact of a single axitinib intravitreal implant in diabetic retinopathy treatment.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, OCUL declined 1.95%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
BEDFORD, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced upcoming presentations at the Angiogenesis, Exudation, and Degeneration 2025 virtual meeting on February 8, 2025.
Presentation Details:
- OTX-TKI From Phase 1 to Phase 3: SOL-1 and SOL-R Trials for Neovascular AMD
Session: V: Imaging and Emerging Therapies for Exudative AMD
Presentation Time: 2:30 PM ET
Presenter: Carl J. Danzig, MD
- Phase 1 Results from Intravitreal Axitinib Implant (OTX-TKI) for the Treatment of Non-Proliferative Diabetic Retinopathy
Session: VII: Diabetic Retinopathy and Retinal Vascular Diseases
Presentation Time: 5:20 PM ET
Presenter: Mark R. Barakat, MD
- Volumetric Macular Fluid Analysis of the Impact of a Single Axitinib Intravitreal Implant (OTX-TKI) from the HELIOS Clinical Trial for Diabetic Retinopathy
Session: VII: Diabetic Retinopathy and Retinal Vascular Diseases
Presentation Time: 5:25 PM ET
Presenter: Justis P. Ehlers, MD
Exact presentation times are subject to change. Expected presentation times can be found on the Program section of the Angiogenesis, Exudation, and Degeneration 2025 conference website.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (axitinib intravitreal injection, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA™ (travoprost intracameral injection or OTX-TIC), which is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.
Follow the Company on its website, LinkedIn, or X.
The Ocular Therapeutix logo and DEXTENZA® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
FAQ
What clinical trials will be presented for OCUL's OTX-TKI at the Angiogenesis 2025 meeting?
When and where will Ocular Therapeutix present its OTX-TKI research in February 2025?
What medical conditions is OCUL's OTX-TKI being developed to treat?
Who are the key presenters for OCUL's research at the Angiogenesis 2025 meeting?
What are the presentation times for OCUL's research at the Angiogenesis 2025 meeting?
